C-reactive protein levels are associated with paraoxonase polymorphism L55M in patients undergoing cardiac SPECT imaging

References

• Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005;25: 29–38.
   PubMed Web of Science ®Google Scholar
• Barter P. The inflammation: lipoprotein cycle. Atheroscler Suppl 2005;6:15–20.
   PubMedGoogle Scholar
• Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006;37:1923–32.
   PubMed Web of Science ®Google Scholar
• Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005;38:153–63.
   PubMed Web of Science ®Google Scholar
• Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498–507.
   PubMed Web of Science ®Google Scholar
• Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001;276: 44444–9.
   PubMed Web of Science ®Google Scholar
• Fortunato G, Di Taranto MD, Bracale UM, Del Guercio L, Carbone F, Mazzaccara C, Morgante A, D'Armiento FP, D'Armiento M, Porcellini M, Sacchetti L, Bracale G, Salvatore F. Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:594–600.
   PubMedGoogle Scholar
• Levy E, Trudel K, Bendayan M, Seidman E, Delvin E, Elchebly M, Lavoie JC, Precourt LP, Amre D, Sinnett D. Biological role, protein expression, subcellular localization and oxidative stress response of paraoxonase2 in the intestine of humans and rats. Am J Physiol Gastrointest Liver Physiol 2007;293:G1252–61.
   Web of Science ®Google Scholar
• Horke S, Witte I, Wilgenbus P, Kruger M, Strand D, Forstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007;115:2055–64.
   PubMed Web of Science ®Google Scholar
• Fortunato G, Rubba P, Panico S, Trono D, Tinto N, Mazzaccara C, De Michele M, Iannuzzi A, Vitale DF, Salvatore F, Sacchetti L. A paraoxonase gene polymorphism, PON1 (55) as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis 2003;167:141–8.
   PubMedGoogle Scholar
• Roest M, Jansen AC, Barendrecht A, Leus FR, Kastelein JJ, Voorbij HA. Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia. Clin Biochem 2005;38:123–7.
   PubMedGoogle Scholar
• Malin R, Rantalaiho V, Huang XH, Wirta O, Pasternack A, Leinonen JS, Alho H, Jokela H, Koivula T, Tanaka T, Okada K, Ochi H, Toyokuni S, Lehtimäki T. Association between M/L55-polymorphism of paraoxonase enzyme and oxidative DNA damage in patients with type 2 diabetes mellitus and in control subjects. Hum Genet 1999;105:179–80.
   PubMedGoogle Scholar
• Janka Z, Juhasz A, Rimanoczy AA, Boda K, Marki-Zay J, Kalman J. Codon 311(Cys3Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol Psychiatry 2002;7:110–2.
   PubMedGoogle Scholar
• Fortunato G, Marciano E, Zarrilli F, Mazzaccara C, Intrieri M, Calcagno G, Vitale DF, La Manna P, Saulino C, Marcelli V, Sacchetti L. Paraoxonase and superoxide dismutase gene polymorphisms and noise-induced hearing loss. Clin Chem 2004;50:2012–8.
   PubMed Web of Science ®Google Scholar
• Martinelli N, Girelli D, Olivieri O, Stranieri C, Trabetti E, Pizzolo F, Friso S, Tenuti I, Cheng S, Grow MA, Pignatti PF, Corrocher R. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest 2004;34:14–20.
   PubMedGoogle Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–43.
   PubMed Web of Science ®Google Scholar
• Zebrack JS, Muhlestein JS, Horne BD, Anserson JL. CRP and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002;39:632–7.
   PubMed Web of Science ®Google Scholar
• Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, Koehler E. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21:1000–8.
   PubMedGoogle Scholar
• Azar RR, Aoun G, Fram DB, Waters DD, Wu AH, Kiernan FJ. Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am J Cardiol 2000; 86:205–7.
   PubMedGoogle Scholar
• Shehadeh J, Lewis BS, Weisz G, David M, Ashkenazi T, Halon DA. Relation between C-reactive protein, treadmill exercise testing, and inducible myocardial ischemia. Am J Cardiol 2004;93:614–7.
   PubMedGoogle Scholar
• Beattie MS, Shlipak MG, Liu H, Browner WS, Schiller NB, Whooley MA. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. Circulation 2003;107:245–50.
   PubMedGoogle Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9.
   PubMed Web of Science ®Google Scholar
• Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, Carabello BA, Russell RO Jr, Cerqueira MD, St John Sutton MG, DeMaria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Nuclear Cardiology. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2003; 108:1404–18.
   PubMed Web of Science ®Google Scholar
• Acampa W, Petretta M, Florimonte L, Mattera A, Cuocolo A. Prognostic value of exercise cardiac tomography performed late after percutaneous coronary intervention in symptomatic and symptom-free patients. Am J Cardiol 2003;91:259–63.
   PubMedGoogle Scholar
• Germano G, Kavanagh PB, Waechter P, Areeda J, Van Kriekinge S, Sharir T, Lewin HC, Berman DS. A new algorithm for the quantitation of myocardial perfusion SPECT. I: technical principles and reproducibility. J Nucl Med 2000;41:712–9.
   PubMedGoogle Scholar
• Berman DS, Abidov A, Kang X, Hayes SW, Friedman JD, Sciammarella MG, Cohen I, Gerlach J, Waechter PB, Germano G, Hachamovitch R. Prognostic validation of a 17-segment score derived from a 20-segment score for myocardial perfusion SPECT interpretation. J Nucl Cardiol 2004;11:414–23.
   PubMed Web of Science ®Google Scholar
• Sharir T, Germano G, Kang X, Lewin HC, Miranda R, Cohen I, Agafitei RD, Friedman JD, Berman DS. Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia and the post-stress ejection fraction. J Nucl Med 2001;42:831–7.
   PubMed Web of Science ®Google Scholar
• Oliveira SA, Mansur AP, Ribeiro CC, Ramires JA, Annichino-Bizzacchi JM. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol 2004;94:73–7.
   PubMed Web of Science ®Google Scholar
• Rios DL, D'Onofrio LO, Cerqueira CC, Bonfim-Silva R, Carvalho HG, Santos-Filho A, Galvão-Castro B. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. Clin Chem Lab Med 2007;45:874–8
   PubMedGoogle Scholar
• Troughton JA, Woodside JV, Yarnell JW, Arveiler D, Amouyel P, Ferrières J, Ducimetière P, Patterson CC, Luc G; PRIME Study Group. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: The PRIME study. Atherosclerosis 2008;197:556–63.
   PubMedGoogle Scholar
• Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004;363:689–95.
   PubMed Web of Science ®Google Scholar
• Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuutila P, Jokela H, Laakso J, Jaakkola O, Solakivi T, Lehtimäki T. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 2001; 79:449–58.
   PubMedGoogle Scholar
• Salonen JT, Malin R, Tuomainen TP, Nyyssönen K, Lakka TA, Lehtimäki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. BMJ 1999;319: 487–9.
   PubMed Web of Science ®Google Scholar
• Malin R, Järvinen O, Sisto T, Koivula T, Lehtimäki T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. Atherosclerosis 2001;157:301–7.
   PubMed Web of Science ®Google Scholar
• Malin R, Laine S, Rantalaiho V, Wirta O, Pasternack A, Jokela H, Alho H, Koivula T, Lehtimäki T. Lipid peroxidation is increased in paraoxonase L55 homozygotes compared with M-allele carriers. Free Radic Res 2001;34: 477–84.
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57–60.
   PubMed Web of Science ®Google Scholar
• Kivimäki M, Lawlor DA, Smith GD, Eklund C, Hurme M, Lehtimäki T, Viikari JS, Raitakari OT. Variants in the CRP gene as a measure of lifelong differences in average C-reactive protein levels: the Cardiovascular Risk in Young Finns Study, 1980–2001. Am J Epidemiol 2007;166:760–4.
   PubMed Web of Science ®Google Scholar
• Rontu R, Ojala P, Hervonen A, Goebeler S, Karhunen PJ, Nikkilä M, Kunnas T, Jylhä M, Eklund C, Hurme M, Lehtimäki T. Apolipoprotein E genotype is related to plasma levels of C-reactive protein and lipids and to longevity in nonagenarians. Clin Endocrinol 2006;64:265–70.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265–76.
   PubMed Web of Science ®Google Scholar